| 000 | 01846 a2200589 4500 | ||
|---|---|---|---|
| 005 | 20250515160908.0 | ||
| 264 | 0 | _c20090707 | |
| 008 | 200907s 0 0 eng d | ||
| 022 | _a1476-5551 | ||
| 024 | 7 |
_a10.1038/leu.2008.402 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aKastritis, E | |
| 245 | 0 | 0 |
_aImproved survival of patients with multiple myeloma after the introduction of novel agents and the applicability of the International Staging System (ISS): an analysis of the Greek Myeloma Study Group (GMSG). _h[electronic resource] |
| 260 |
_bLeukemia _cJun 2009 |
||
| 300 |
_a1152-7 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article | ||
| 650 | 0 | 4 | _aAge Factors |
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 | _aAnalysis of Variance |
| 650 | 0 | 4 |
_aBoronic Acids _xtherapeutic use |
| 650 | 0 | 4 | _aBortezomib |
| 650 | 0 | 4 | _aDrug Evaluation |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aGreece |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aLenalidomide |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 |
_aMultiple Myeloma _xdiagnosis |
| 650 | 0 | 4 |
_aNeoplasm Staging _xstatistics & numerical data |
| 650 | 0 | 4 |
_aPyrazines _xtherapeutic use |
| 650 | 0 | 4 | _aRetrospective Studies |
| 650 | 0 | 4 | _aSurvival Rate |
| 650 | 0 | 4 |
_aThalidomide _xanalogs & derivatives |
| 650 | 0 | 4 | _aTreatment Outcome |
| 700 | 1 | _aZervas, K | |
| 700 | 1 | _aSymeonidis, A | |
| 700 | 1 | _aTerpos, E | |
| 700 | 1 | _aDelimbassi, S | |
| 700 | 1 | _aAnagnostopoulos, N | |
| 700 | 1 | _aMichali, E | |
| 700 | 1 | _aZomas, A | |
| 700 | 1 | _aKatodritou, E | |
| 700 | 1 | _aGika, D | |
| 700 | 1 | _aPouli, A | |
| 700 | 1 | _aChristoulas, D | |
| 700 | 1 | _aRoussou, M | |
| 700 | 1 | _aKartasis, Z | |
| 700 | 1 | _aEconomopoulos, T | |
| 700 | 1 | _aDimopoulos, M A | |
| 773 | 0 |
_tLeukemia _gvol. 23 _gno. 6 _gp. 1152-7 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1038/leu.2008.402 _zAvailable from publisher's website |
| 999 |
_c18668218 _d18668218 |
||